- Services
- ABL1 Kinase Domain Mutation Analysis
- Chimerism Assessment by Polymorphic Microsatellite Markers
- Detection of BCR ABL Major Fusion Transcripts
- Detection of BCR ABL Minor Fusion Transcripts
- EndLeukemia RNA Translocation Assay Analysis
- FIP1L1-PDGFRA Fusion Transcript Detection
- FLT3 Mutational Analysis
- hMLH1 Methylation Status
- Immunoglobulin Heavy Chain Gene Rearrangement
- Inv(16)(p13.1q22);CBFB-MYH11 Fusion Transcript Detection
- JAK2 p.V617F Mutational Analysis
- EndLeukemia Assay
- MD EndLymphoma Mutation Analysis
- MD FLT3-ITD Follow up Mutation MRD Analysis
- MD Focused Pharamacogenomics Genotyping Assay
- MD HPV Liquid Biopsy
- MD NPM1 MRD Mutation Analysis
- MDA Mutation Analysis Precision Panel Liquid Biopsy
- MGMT Methylation Status
- Microsatellite Instability Analysis (Tumors)
- PML-RARA/t(15;17) Fusion Transcript Detection
- RUNX1-RUNX1T1/t(8;21)(q22;q22) Fusion Transcript Detection
- Somatic Hypermutation Analysis, IGH
- T cell Receptor Beta Gene Rearrangement
- T cell Receptor Gamma Gene Rearrangement
- TGFB1 Polymorphism Real-Time PCR Genotyping
MD FLT3-ITD Follow up Mutation MRD Analysis
Indication
The treatment of acute myeloid leukemia (AML) has become a model for precision medicine. The FLT3 ITD minimal residual disease (MRD) test is a next-generation sequencing (NGS)-based, targeted deep-sequencing assay designed to detect internal tandem duplications (ITDs) in the FLT3 gene, ranging from 3 base pairs to over 200 base pairs in size. Once a specific ITD has been identified in an initial sample, it can be accurately monitored in subsequent samples with a sensitivity of 0.005%. This capability allows for the detection of the persistent FLT3 ITD mutation even in patients who show no visible signs of disease, helping clinicians determine whether to continue or adjust treatment. MRD detection via NGS has proven valuable in predicting clinical outcomes and providing actionable results, facilitating early intervention, confirming disease status before transplant, and bolstering confidence in remission status.
Methodology
Next-generation sequencing of PCR products is employed to identify DNA sequences corresponding to previously detected mutations identified at diagnosis.
Test Parameters
Clinical specimens were reviewed for following FLT3 ITD transcripts.
Turnaround Time
10 days
Sample Requirements
- 10 ml peripheral blood (PB) in purple-top (lavender top) tube (EDTA Vacutainer), sent on wet ice
or
- 2–5 ml of bone marrow aspirate (BM), sent on wet ice
CPT Codes
81245
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.